FDA Notes Lack Of Proof For Cancer Risk, But Lantus Isn't Out Of The Woods Yet
This article was originally published in The Pink Sheet Daily
Executive Summary
Commercial impact on the top-selling insulin is questionable, as 2009 studies showing the risk had already been seen as sketchy and did not appear to dent sales or competitive profile.